Regenerative medicine company CollPlant today released information on its planned initial public offering, looking to bring in $25 million.
CollPlant produces wound care and regenerative devices based on plant-derived collagen. Their products include the Vergenix FG flowable gel intended to treat chronic and acute wounds.
The wound-filling gel utilizes Israel-based CollPlant’s proprietary tobacco plant-based technology, which the company claims allows for large scale production of recombinant human collagen.
